Navigation Links
Leading global Big Pharma companies of 2005

I always look forward to writing this particular article with great anticipation! Why, you say? It is part of an annual ritual that I have followed with eagerness as I grew up in the pharmaceutical industry, initiating in my 10 years at Pfizer (way before Pfizer was the juggernaut it is today). At Pfizer, we were all anxious to see the annual company ranking results ......

Full article >>> an old friend and colleague who was retiring from Pfizer the week that I was there, after 31 years with the company. In fact, he and I started at Pfizer the same year (wow, I was really feeling old).

As I toured Pfizer Brazil's offices, we were reminiscing of the old days when Pfizer's offices in most Latin American countries were usually located 45 minutes to an hour from city centers a......

Full article >>> >N/ARoche* (Swiss + Chugai)$15.7N/A99Wyeth (U.S.)$15.3+10%108Bristol-Myers Squibb$15.3<1%>1111Eli Lilly (U.S.)$14.7+12%1210Abbott Labs (U.S.)$14.0+16%
Full article >>> les from acquisition of Japanese company Chugai but does not include sales from majority-owned position in Genentech
** merger of Yamanouchi and Fujisawa to become Astellas
*** does not include recently-announced acquisition of Schering AG
**** merger in September, 2005 of Daiichi and Sankyo

By the way, as a manner of comparison, let's take a look at the rankings of the pharm......

Full article >>> re within the top 30 companies, Amgen and Genentech, with Amgen close to breaking into the top 10 companies although its growth is slowing down; Genentech continues to move up in the ranks and actually finished the year with a market cap higher than Amgen's - approaching $100 billion
  • The Japanese companies continue to globalize due to the weakness of their own home market and inc......

    Full article >>> 6Novartis$4.518.0%7Roche (includes Chugai)$4.226.8%8Merck$3.817.3%9Eli Lilly$3.020.4%10Amgen$2.319.2%11Schering-Plough$1.925.0%
    Full article >>> >Abbott Labs at about 13% of sales is on the low side while Eli Lilly is aggressively investing (20% of sales); Baxter, at about 17% of sales, is just slightly above the average for the industry.

    Note that, on average, 50% of a Big Pharma's R&D budget is being spent on the development of in-licensed drugs (from smaller companies), with some companies spend......

    Full article >>> altimore, Chicago, Cleveland, and Denver. Rosen is also a founder and board member of the Illinois Biotechnology Industry Organization. He can be reached at

  • The opinions expressed herein or statements made in the above column are solely those of the author and do not necessarily reflect th......

    Full article >>>
    '"/> By Michael Rosen 05/09/06

    Related biology technology :

    1. Leading cancer institute to install three TomoTherapy systems
    2. The state of global biotech: An Ernst & Young perspective
    3. Doyle announces new energy, global warming policies
    4. Lucigen Corp. enters global licensing agreement
    5. Work-life imbalance - A global problem getting worse
    6. Learning to swim in the global talent pool
    7. Federal and global guidelines on stem cell research offer a level playing field
    8. Wisconsin plant is part of NCRs global RFID initiative
    9. Whither Wisconsin manufacturing in the new global economy?
    10. In the wake of Katrina, more questions than answers about global climate change
    11. Is America prepared to win the global skills race?
    Post Your Comments:

    (Date:12/1/2015)... ... December 01, 2015 , ... ... in scientifically backed, age-defying products, is featured as the cover story and ... success and unrivaled opportunities that Nerium provides. Success from Home magazine routinely ...
    (Date:12/1/2015)... 1, 2015 Dr. Harry Lander , President of Regen, ... Chief Science Officer and recruits five distinguished ... , President of Regen, expands his role to include ... recruits five distinguished scientists to join advisory team ... his role to include serving as Chief ...
    (Date:12/1/2015)... DUBLIN , December 1, 2015 /PRNewswire/ ... the addition of the  "2016 U.K. Virology ... Segment Forecasts for 100 Tests, Supplier Shares ... Opportunities"  report to their offering.  --> ... of the  "2016 U.K. Virology and Bacteriology ...
    (Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group ... in the Santiago Marriott. The Global Stem Cells Group GMP facility is equipped ... of qualified medical researchers and practitioners, experienced in administering stem cell protocols using ...
    Breaking Biology Technology:
    (Date:11/12/2015)... 2015  Arxspan has entered into an agreement ... for use of its ArxLab cloud-based suite of ... partnership will support the institute,s efforts to electronically ... information internally and with external collaborators. The ArxLab ... the Institute,s electronic laboratory notebook, compound and assay ...
    (Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
    (Date:11/9/2015)... SAN JOSE, Calif. , Nov. 9, 2015 /PRNewswire/ ... of human interface solutions, today announced broader entry into ... of vehicle-specific solutions that match the pace of consumer ... drivers, and biometric sensors are ideal for the automotive ... the vehicle. Europe , ...
    Breaking Biology News(10 mins):